Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Inhaled PC786 in Healthy Subjects and Subjects with Mild Asthma
NCT03236233Phase 1Completed
- Sponsor
- Pulmocide
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of PC786 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pulmocide. Primary endpoints: Number of participants reporting one or more treatment-emergent adverse events, Number of participants who discontinue due to an adverse event and 4 more. Started Jun 2017; status: completed.
02
Drugs
PC786
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03236233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236233.